Organon & Co. develops and delivers health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding or hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

Organon & Co.

RBC Capital analyst Matthew Hedberg maintained a Buy rating on JFrog today and set a price target of $118.00. Hedberg covers the Technology sector,...

JFrog (FROG) Gets a Buy from RBC Capital

Morgan Stanley analyst maintained a Buy rating on Cogna Educacao S.A. today and set a price target of BRL3.40. Cogna Educacao S.A. has an analyst c...

Morgan Stanley Sticks to Their Buy Rating for Cogna Educacao S.A. (COGN3)

Orogen Royalties ( ($TSE:OGN) ) has issued an update. Orogen Royalties has acquired a 2% net smelter return royalty on Silver North Resources’ Hald...

Orogen Royalties Secures Uncapped NSR on High-Grade Yukon Silver Project

Origin Enterprises plc ( ($GB:OGN) ) has issued an announcement. Origin Enterprises plc has disclosed that Cobas Asset Management has increased its...

Cobas Asset Management Lifts Stake in Origin Enterprises to 9.1%

In a report released today, Andres Coello from Scotiabank maintained a Buy rating on Cogna Educacao S.A., with a price target of BRL3.90. According...

Cogna Educacao S.A. (COGN3) Receives a Buy from Scotiabank

Jfrog Ltd. (($FROG)) has held its Q2 earnings call. Read on for the main highlights of the call. JFrog’s latest earnings call struck a confident to...

JFrog Earnings Call Highlights Cloud, Security, Growth

In a report released today, Koji Ikeda from Bank of America Securities reiterated a Buy rating on JFrog, with a price target of $110.00. According ...

JFrog (FROG) Gets a Buy from Bank of America Securities

TD Cowen analyst Andrew Sherman reiterated a Buy rating on JFrog yesterday and set a price target of $120.00. Sherman covers the Technology sector,...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OGN	$13.78	+0.04%	1.27M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OGN	$13.78	+0.0%	1.27M
3
4
5
6

OGN

Get Organon & Co. Data in Excel

Get Organon & Co. Data in Excel